Genome Editing and Engineering

Herausgeber: Appasani, Krishnarao

• Gebundenes Buch

Produktbeschreibung

A complete guide to endonuclease-based genomic engineering, from basic science to application in disease biology and clinical treatment.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Cambridge University Press
• Seitenzahl: 536
• Erscheinungstermin: 19. Februar 2019
• Englisch
• Abmessung: 250mm x 175mm x 33mm
• Gewicht: 1096g
• ISBN-13: 9781107170377
• ISBN-10: 1107170370
• Artikelnr.: 50104176

Inhaltsangabe

List of contributors; Forewords; Preface; List of abbreviations; Part I.
Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and
Regulatory Networks: 1. Introduction to genome editing and engineering:
from Talens, ZFNs and CRISPRs to molecular surgery; 2. Targeted genome
editing techniques in C. elegans and other nematode species; 3. Unbiased
detection of off-target cleavage by CRISPR-Cas9 and TALENs using
integrase-defective lentiviral vectors; 4. In vivo studies of miRNA target
interactions using site-specific genome engineering; 5. Don't kill the
messenger: employing genome editing to study regulatory RNA interactions;
Part II. Genome Editing in Model Organisms: 6. Genome editing in the
crustacean Daphnia magna using CRISPR/Cas and TALEN systems; 7.
Leapfrogging: a method for targeting genome editing to the germline; 8.
Genome editing with desired mutations (knock-in) by CRISPR in model
organisms; 9. Genetically engineered pig models for human diseases using
ZFNs, TALENs and CRISPR-Cas9; 10. Gene editing to create agricultural and
biomedical swine models; 11. Generation of new model cell lines using ssODN
knock-in donors and FACS-based genome editing; Part III. Technology
Development and Screening: 12. CRISPR genome editing in mice; 13. Detection
of insertion/deletion (indel) events after genome targeting: pros and cons
of the available methods; 14. Application of TAL proteins and the CRISPR
system to purification of specific genomic regions for locus-specific
identification of chromatin-associated molecules; 15. Application of CRISPR
for pooled, vector-based functional genomic screening in mammalian cell
lines; 16. Generation and utilization of CRISPR/Cas9 screening libraries in
mammalian cells; Part IV. Genome Editing in Stem Cells and Regenerative
Biology: 17. Targeted genome editing using nuclease assisted vector
integration; 18. Genome engineering using Sleeping Beauty transposition in
vertebrates; 19. Genome editing of pluripotent stem cells; 20. Principles
for targeting adult tissue stem cells to achieve durable gene and
gene-editing therapies; 21. Therapeutic genome editing in human
hematopoietic stem and progenitor cells; Part V. Genome Editing in Disease
Biology: 22. CRISPR/Cas9-Based in vivo models of cancer; 23. Inducible
CRISPR-based genome editing for the characterization of cancer genes; 24.
Genome editing for retinal diseases; 25. Manipulation of long non-coding
RNAs in cardiovascular disease using genome-editing technology; 26. Gene
silencing, disruption and latency reactivation with RNA-based and gene
editing CRISPR/Cas, ZFN and TALEN technologies for HIV-1/AIDS therapies;
27. Use of the CRISPR-Cas9 system for genome editing of immune system
cells, defense against HIV-1 and cancer therapies; 28. Harnessing
therapeutic potential of long non-coding RNAs in immunity; Part VI. Legal
(Intelluctual Property) and Bioethical Issues of Genome Editing: 29.
Patening of CRISPR-based inventions; 30. Patent, ownership, and licensing
issues of CRISPR-based genome editing: impact on universities and their
licensees; 31. The ethics of human genome editing; 32. Regulating human
genome editing: negotiating ethical concerns through science and policy;
Index.